(NNT) to avoid one terminal event of natural causes was calcuReduction in natural death and renal failure from a systematic lated at only 11.6.
screening and treatment program in an Australian Aboriginal
Conclusions. Falling rates of deaths and renal failure in the community.
whole community support marked benefit of the program. MilBackground. Australian Aborigines in remote areas are exlions of dollars have been saved, based on avoidance of dialysis periencing an epidemic of renal and cardiovascular disease.
alone, but the reduction in premature death is the greater benefit. In November 1995, we introduced a renal and cardiovascular Chronic disease programs like this are enormously effective, treatment program into the Tiwi community, which has a threeand should be introduced into to all high-risk communities as to fivefold increase in death rates and a recent annual incidence a matter of urgency. of treated end-stage renal disease (ESRD) of 2760 per million. Our previous study described an estimated 50% reduction in renal failure and all-cause natural deaths in the treatment group through December 31, 1998. We now describe a reduction in End of the Northern Territory (NT) were estimated at hundred and sixty-seven people, or 30% of the adult population, have been enrolled, with mean follow up of 3.39 years.
$112,169:$71,000 for dialysis treatments alone and Rates of terminal endpoints were compared on an intention-$41,169 for intercurrent hospitalizations [3] . These funds to-treat basis with those of 327 historical controls matched for could be spent otherwise on prevention and primary care baseline disease severity, who were followed for a mean of in this seriously under-resourced environment. However, 3 .18 years in the pre-treatment program era, against a backpremature death in young and middle aged adults is the ground of no treatment or inconsistent changing treatment.
Results. Terminal events occurred in 38 controls and 23 peogreater tragedy.
ple in the treatment group. The estimated rate of natural deaths These problems have been especially serious in the in the treatment group was 50% that of the controls, (P ϭ 0.012);
Tiwi Islands (population about 1800, about 50% age 20ϩ the rate of renal deaths was 47% (P ϭ 0.038) and the rate of years), with high rates of premature adult death, and an non-renal deaths was 54% that of controls (P ϭ 0.085 among the low death rates of people without overt albuminuria,
In a community-wide screening program starting in and questionable among people with glomerular filtration rates (GFRs) Ͻ60 mL/min. The number of people needed to treat
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longitudinal study showed that albuminuria marked all increased to 8 mg for people above the blood pressure goal, and later in the program, for people of substantial the future risk for renal deaths, and it also strongly predicted non-renal deaths, both cardiovascular and nonbody size, or with resistant overt albuminuria (ACR 60 g/mol and more). After the first year we used full-dose renal non-cardiovascular. Overall, pathologic albuminuria marked 75% of the risk for all-case natural death perinopril in people with serious renal insufficiency, finding little justification for use of smaller doses [10] . Calover the observation period [4] .
Use of antihypertensive drugs, including angiotensin cium channel blockers were added if needed for blood pressure control, and diuretics were added for further converting enzyme inhibitors (ACEi), was gradually increasing in the Tiwi community through the early 1990s, blood pressure control or fluid retention. Other elements of the program included health education, and attempts but systematic management of the burden of disease exposed by our studies seemed beyond the capabilities of to control blood glucose levels and lipids, when needed. Enrollment into the treatment program was prioritized the health services in place. Therefore, in November 1995 we introduced a formal program to alter renal and to some extent by disease severity. This included prioritized enrolment of several people with serious renal incardiovascular disease outcomes.
We previously described the results of this program sufficiency who were deteriorating on their current management. Participants were followed until they died, up through December 1998, when the maximum time on treatment was 3.1 years, average time on treatment started dialysis, or through June 30, 2000, 4.56 years after the first person was enrolled on the program. People was 2.1 years, and total follow up was 549 person-years [7] . The results were dramatic: blood pressures fell markdying an unnatural death before the end of the observation period were censored from the cohort at the time edly and progression of albuminuria and decline in GFR were arrested on a group basis. When compared with of that event. Due to irresolution in the first few months of the program, the treatment group for the final analysis historical controls who were followed for a total of 543 years in the pre-program era, the treatment group showed included only people prescribed treatment for at least a month. an estimated 50% fall in rates of all-cause natural deaths
After an initial training period, the program was run and renal failure.
by local health workers and community liaison workers. We now describe the survival of the treatment cohort They used community lists and recall systems, relied through June 30, 2000. Extended time on treatment has heavily on algorithms for testing and treatment, and were allowed a comparison with an expanded group of conrequired to become familiar with only a limited number trols, followed for a longer period, beginning with baseof medicines. They were supported, mostly remotely, by line studies done earlier in the 1990s.
a nurse coordinator and a doctor authorizing treatment.
The program was modeled around collaborative, rather METHODS than authoritative lines, and often operated outside the The albumin creatinine ratio (ACR, g/mol) on a ranclinic. dom urine specimen was used as an indicator of renal It was not ethical to have an untreated control group, disease and its severity [5, 6] . The following categories nor feasible to have one treated with different regimens; were employed: Ͻ3.4, normal; 3.4 to 33, microalbuminthus the outcomes of the treatment group were compared uria, and 34ϩ, overt albuminuria. Overt albuminuria was with those of historical controls matched for disease sefurther categorized thus: 34 to 99, moderate; 100 to 199 verity, to the extent possible. These controls were people heavy; 200ϩ intense. Serum creatinine levels were meascreened and followed in the pre-treatment-program era, sured, and GFR was estimated by the Cockcroft and who were selected, blind to their ultimate outcome, based Gault formula [8] .
on the following criteria on their baseline screening: People eligible for treatment were those with confirmed hypertension (Ն140/90 on two occasions), all dia-(1) BP Ն140/90 and diabetes or pathologic albuminbetics with confirmed pathologic albuminuria (ACR 3.4 uria (3.4ϩ). g/mol and above), and all persons with confirmed overt (2) Diabetics with pathologic albuminuria (ACR 3.4ϩ). albuminuria, (ACR 34ϩ), regardless of blood pressure (3) Overt albuminuria (ACR 34ϩ) regardless of blood or diabetes. Exclusions were people who were pregnant, pressure or diabetes. breast feeding or known to be allergic to ACEi.
Medical treatment centered around the use of the longPeople with a single observation of elevated blood acting angiotensin-converting enzyme inhibitor, perindopressure, but without other risk factors, were not included pril (Coversyl, Servier), and attempts to keep blood presas controls. sures below 130/85 in the first two years of the program, The course of controls was followed against a backand below 125/70 in the last two years [9] . The intended ground of no treatment or changing treatment, from their baseline examination until they died, started dialminimum perindopril dose was 4 mg, but the dose was died or developed renal failure, one died a suicide death, censored 4.56 years after their qualifying observation, six became normotensive, two were "false starts", six the maximum follow-up period of people in the treatbecame pregnant, one was breast feeding, six had adment program. People who died unnatural deaths before verse effects (3 with cough, 2 with angioedema, 1 with 4.56 years of follow-up were right-censored at time of itching), six decided to quit, three moved, and two went death.
onto palliative care. The fate of all persons was ascertained, and a cause Three hundred and twenty-seven people were identiof death allocated by review of clinic and hospital records fied as controls. They were followed for a total of 1041 and death certificates. Deaths were categorized as allyears, with a mean of 3.18 (1.48) years. One hundred cause natural death (non-renal and renal deaths), renal and seventy-one (52.3%) were ultimately enrolled in the deaths (dialysis or death with chronic renal failure), nontreatment program. The other 156 were not, for reasons renal deaths, cardiovascular deaths (primary or contribthat included interim death or renal failure, declining uting), and non-renal, non-cardiovascular deaths. These treatment, failure to confirm eligibility criteria, presence are described in more detail elsewhere [4] . For renal of exclusion criteria, or moving from the area. deaths and for the combined end point of natural death
The profiles of the treatment and control groups are and renal failure, the survival interval of people starting compared in Table 1 . The treatment group tended to be dialysis ended when treatment began.
older than the controls, was more often diabetic, and For the treatment cohort, data were analyzed on an tended to have higher ACR levels. Sixty-one of the treat-"intention to treat" basis. Terminal events were exment group, or 22.8%, had been prescribed enalapril or pressed as rates per 100 person-years. Hazard ratios for captopril prior to enrollment. terminal events were calculated by the Cox proportional Medical treatment intensified over time. Of people hazard method after demonstration that the assumptions participating at three years, 2% were prescribed 2 mg of the proportional hazard model were not violated. Surperindopril, 32% were prescribed 4 mg perindopril and vival statistics also were compared by Kaplan Meier 66% were prescribed 8 mg perindopril. Seventeen permethods. STATA statistical software was used for data cent of people (all on maximum perindopril) were taking analysis [11] . a single additional medicine (calcium channel blockers or diuretics) and 5.7% were taking both agents. By self-RESULTS report in the middle and later parts of the program, 66% of people were taking their medicines "most of the time," Two hundred and sixty-seven people were enrolled in 27% "sometimes" or "occasionally", and 7% "rarely or the treatment program, or about 30% of all adults (20ϩ never" [12] . years). Baseline urine ACR levels and serum creatinine Over the course of treatment, there was a rapid, marked, levels were available in 265 of these people. They were and sustained drop in blood pressure, and a retardation followed for a total of 898 years, with a mean (SD) of 3.36 (SD 1.16) years. Fifty-six people were no longer in of both the progression of albuminuria and the loss of
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the treatment group, and a 57% reduction in renal deaths, both of which are significant. It also shows a 46% reduction in non-renal deaths, a 49% reduction in deaths with a cardiovascular component, and a 61% reduction in non-renal, non-cardiovascular deaths, although these associations escaped significance. Table 4 shows the estimated reduction in all-cause natural death in the treatment group according to participant characteristics and baseline renal function, with adjustment for age and sex and ACR. Although the smaller numbers reduce the significance of the associations, there was a suggestion of treatment benefit in people with elevated blood pressures as well as those with lower blood pressures, in non-diabetics as well as diabetics, and in people who had previously been on ACEi treatment as well as those who had not. The data confirm lack of benefit in people without overt albuminuria. Among rates of natural death, which was significant.
Survival benefit of treatment took about two years to become manifest as shown in Figure 2 . GFR on a group basis. These observations are described Figure 3 shows that the numbers of natural deaths and separately [7, [12] [13] [14] .
of the people starting dialysis in the entire community Sixty-one people reached a terminal event of natural began to fall at about the time of enrollment of substancause: 38 in the control group, and 23 in the treatment tial numbers of people in the treatment program. Aggregroup. Twenty-five (41%) of these were renal deaths, of gate data from other Aboriginal communities across the whom 21 went onto dialysis. Thirty-six deaths (59%)
Top End of the NT, where screening and treatment poliwere non-renal. Twenty-nine deaths (45.9%) had a pricies are changing more slowly, have not reflected the mary or underlying cardiovascular cause.
same sharp changes. Figure 1 summarizes the treatment program effect. It shows that rates of all-cause natural deaths were strongly DISCUSSION related to baseline ACR category, and that rates were
The introduction of a systematic screening and treatlower in the treatment group than in controls for persons ment program into this high risk community was associin every category of overt albuminuria. No difference ated with an estimated 50% reduction in rate of natural was apparent among the low death rates of people with deaths and 57% reduction in rate of renal failure at an lower ACRs.
average follow up of 3.39 years, when compared with Table 2 shows the numbers and rates of terminal the fate of people with similar disease severity in the events by baseline ACR in the control and treatment pre-treatment program era. groups. It shows lower rates of all-cause natural death Heightened awareness, health education, and better for the treatment groups in all categories of overt albumetabolic management were all elements of the prominuria, illustrated in Figure 1 . It also shows the numbers gram, but most of the treatment benefit was probably and rates by category of death, with people with ACR due to medication for renal and cardiovascular protec-100ϩ consolidated into a single group, due to smaller tion. The fall in blood pressures, the reduced progression numbers of type-specific events. All renal deaths but one of ACR, and reduction in the loss of GFR, predict reducwere segregated among people with baseline ACR 100ϩ (the other with a baseline ACR of 99.5), and the rate in tions in renal and all-cause natural deaths, as we have observed. the treatment group was apparently lower than in controls. Rates of non-renal deaths, cardiovascular deaths
There are many problems with the methods used to estimate treatment benefit in this program. One serious and non-renal non-cardiovascular deaths were lower also for the treatment group than for controls in aggregate, source of understatement of treatment benefit was the intentional recruitment into the treatment group of sevand for people in both categories of overt albuminuria. Table 3 summarizes the hazard ratios of the treatment eral people with progressive renal insufficiency who were failing their status quo management. This reduced the group relative to controls, for each category of endpoint, adjusted for age, sex and baseline ACR level. It shows real rates of renal failure in the natural history and exacerbated rates of renal failure early in the treatment proa 50% reduction in rates of all-cause natural deaths in of people were taking medicines occasionally, or not at Non-renal, non-cardiovascular 0.39 (0.14-1.14), P ϭ 0.085 all. Hypertension, and therefore eligibility for treatment even in the absence of albuminuria, should be redefined as BP Ն130/80 in this high risk population [10] . Blood pressure control was not optimum; at two years 44% of gram. The use of historical controls to estimate treatment the treatment group had BPs Ͼ125/70, a desirable level benefit is also imperfect. First, the courses of the groups for people with renal disease [9] . Control of blood gluwere not precisely contemporaneous. Second, the concose and lipid levels needs to improve. According to the trols were followed over a background of no treatment HOPE study, application of ACEi treatment in diabetics and changing treatment, which could not be precisely can be expanded [15] . Finally, wider use of other renaldelineated. Third, eligibility of controls by ACR levels protective drugs such as angiotensin receptor blocking was assessed on a single examination, whereas confirmaagents, and possibly higher doses of ACEi in poor retion was required for the treatment group while people sponders, should be applied [16] . with a single elevated blood pressure, but no other eligiTreatment appeared to be of benefit in people with bility criteria, were excluded as controls. Fourth, more normal blood pressures at baseline and those with hyperthan half the control group subsequently entered the tension, in non-diabetics as well as diabetics, and in peotreatment program, and having avoided death and renal ple who had previously received ACEi treatment, as failure in the pre-program era, thus might have defined well as those who had not. Benefit was apparent among themselves as "survivors," potentially inflating the treatpeople with all categories of overt albuminuria, who ment program benefit. However, the greater age, more comprised 64% of the treatment group, although not diabetes, and more severe renal disease in the treatment among the very low death rates of people with lower group, all survival disadvantages, could contribute to levels of urinary albumin. Finally, treatment appeared understatement of the program's benefit. Ultimately, to be more effective in avoiding end points in people trends in community-based deaths and renal failure supwith better preserved GFRs. However, the clear improvement in blood pressure in people with low ACRs ported the marked impact of the program, although the and low GFRs people [7, 12, 13, 14] suggest that survival that the reductions in blood pressure, progression of ACR and loss of GFR that occur with treatment take benefit will become manifest in these groups over a longer period of follow-up period.
time to translate into measurable survival benefits.
Our data suggest that a terminal end point was avoided Survival benefit was reflected in reduced renal and nonrenal deaths. Reduction in renal deaths has imporin about 23 people in the treatment cohort: approximately 13 renal deaths and 10 non-renal deaths. Thus, tant implications for morbidity, mortality and costs, while the 54% reduction in nonrenal deaths has a tremendous the number of people needed to treat (NNT) over an average of 3.39 years to avoid a terminal end point was impact in terms of premature death avoided or postponed. only 11.6, and the NNT to avoid one renal death was 26.7. Thus, the program was both effective and efficient Our demonstration that albuminuria predicts nonrenal as well as renal deaths [4] , anticipates a reduction in avoiding unwanted outcomes. It also saved costs. Baker et al estimated the average annual cost per patient in in natural deaths and renal failure through interventions that retard the progression of albuminuria. A fall in the treatment cohort over the first three years of the program was $1,383 [17] ; this would fall as people move cardiovascular deaths is expected in view of the antihypertensive and cardiac and vascular-sparing effects of from the start-up to the maintenance phase. Using dialysis cost estimates of You et al [3] and the average surACEi. However, the associations of non-cardiovascular non-renal deaths with albuminuria and the apparent benvival of people on dialysis described by Spencer et al [2] , it was estimated that between $884,400 and $4,057,200 efit with treatment lend themselves less readily to traditional explanations.
was saved in those first three years, through avoidance or postponement of dialysis alone. The range depends About two years of treatment was required before reduction in all-cause natural death became apparent.
on whether ESRD incidence would have plateaued at the pre-program peak of 2760 per million (pm), or would This reflects, in part, the prioritization of the sickest people for early entry into the program. It also implies have continued to double every four years in the absence of intervention [17, 18] . The analysis through mid-2000
